Stocks · News reference
Topline results from the Phase 3 ECLIPSE 1 trial demonstrate that the combination of elebsiran, an siRNA licensed from Alnylam, and tobevibart achieved significant virologic response in patients with hepatitis delta.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Alnylam Pharmaceuticals announced that its collaborator, Regeneron Pharmaceuticals, shared initial positive results from a first-in-human trial of CIDEBsiRNA in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD).
DelveInsight released a comprehensive report on the Type 2 Diabetes competitive landscape, analyzing 200+ pipeline drugs from 170+ active players. The report highlights recent approvals including Eli Lilly's FOUNDAYO (orforglipron) and Novo Nordisk's once-weekly insulin options, alongside promising pipeline therapies targeting various mechanisms of action. Key developments include positive Phase III results for CagriSema, elecoglipron, and other novel GLP-1 receptor agonists, with approximately 60+ drugs in late-stage development.
Citigroup has revised its price target for Alnylam Pharmaceuticals, Inc., lowering it from $320 to $250.
Five-year study results indicate that continuous treatment with Amvuttra significantly reduces the risk of death and cardiovascular events in patients with ATTR cardiomyopathy.
Filed: 2026-11-05 AccNo: 0001178670-26-000080 Size: 152 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events